That's an interesting discussion. My colleague from the U.S. will probably go into this. The problem with the extension of IP is that you're going to pay a lot more for this antibiotic when it's being reimbursed through your Canadian health care system. It is an incentive for sure to allow pharmaceutical companies to be more interested in that market. At the same time, if you don't rely on a private health care system, I'm not sure any analysis has been done on whether in the long run that is a good return on investment.
I think things like prizes and the grant system to help pay for the research and in return request good stewardship and lower prices for the end products that are paid for by the taxpayer are things that need to be considered.